• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

4-（9-蒽基）-1-（2,4-二甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮

4-(9-Anthr-yl)-1-(2,4-dimethoxy-phen-yl)spiro-[azetidine-3,9'-xanthen]-2-one.

作者信息

Baktır Zeliha, Akkurt Mehmet, Jarrahpour Aliasghar, Ebrahimi Edris, Büyükgüngör Orhan

出版信息

Acta Crystallogr Sect E Struct Rep Online. 2009 Jun 20;65(Pt 7):o1623-4. doi: 10.1107/S1600536809022739.

DOI:10.1107/S1600536809022739
PMID:21582891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2969353/
Abstract

The title compound, C(37)H(27)NO(4), crystallizes with two mol-ecules in the asymmetric unit. The β-lactam ring of each mol-ecule is very nearly planar, with maximum deviations of 0.001 (2) and 0.017 (2) Å in the two mol-ecules. The crystal structure is stabilized by inter-molecular C-H⋯O and C-H⋯N contacts, as well as by weak C-H⋯π inter-actions.

摘要

标题化合物C(37)H(27)NO(4)在不对称单元中含有两个分子。每个分子的β-内酰胺环几乎是平面的，两个分子中的最大偏差分别为0.001 (2) Å和0.017 (2) Å。晶体结构通过分子间的C-H⋯O和C-H⋯N接触以及弱的C-H⋯π相互作用得以稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a37/2969353/05ccdc9bc881/e-65-o1623-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a37/2969353/c230a6580401/e-65-o1623-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a37/2969353/05ccdc9bc881/e-65-o1623-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a37/2969353/c230a6580401/e-65-o1623-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a37/2969353/05ccdc9bc881/e-65-o1623-fig2.jpg

相似文献

1
4-(9-Anthr-yl)-1-(2,4-dimethoxy-phen-yl)spiro-[azetidine-3,9'-xanthen]-2-one.4-（9-蒽基）-1-（2,4-二甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Jun 20;65(Pt 7):o1623-4. doi: 10.1107/S1600536809022739.
2
4-(9-Anthr-yl)-1-(3-bromo-phen-yl)spiro-[azetidine-3,9'-xanthen]-2-one.4-（9-蒽基）-1-（3-溴苯基）螺-[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Sep 26;65(Pt 10):o2522-3. doi: 10.1107/S1600536809037830.
3
4-(9-Anthr-yl)-1-(1-naphth-yl)spiro-[azetidine-3,9'-xanthen]-2-one n-hexane hemisolvate.4-（9-蒽基）-1-（1-萘基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮正己烷半溶剂化物
Acta Crystallogr Sect E Struct Rep Online. 2008 Nov 29;64(Pt 12):o2466-7. doi: 10.1107/S1600536808039305.
4
4-(9-Anthr-yl)-1-phenylspiro-[azetidine-3,9'-xanthen]-2-one.4-（9-蒽基）-1-苯基螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Feb 11;65(Pt 3):o501-2. doi: 10.1107/S1600536809004255.
5
4-(9-Anthr-yl)-1-(2-methoxy-phen-yl)spiro-[azetidin-3,9'-xanthen]-2-one.4-（9-蒽基）-1-（2-甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Feb 28;65(Pt 3):o626-7. doi: 10.1107/S1600536809005200.
6
4-(9-Anthr-yl)-1-(4-methoxy-phen-yl)spiro-[azetidin-3,9'-xanthen]-2-one.4-（9-蒽基）-1-（4-甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2008 Apr 26;64(Pt 5):o902-3. doi: 10.1107/S1600536808010908.
7
(E)-1-(2,4-Dinitro-phen-yl)-2-[1-(4-fluoro-phen-yl)ethyl-idene]hydrazine.（E）-1-（2,4-二硝基苯基）-2-[1-（4-氟苯基）亚乙基]肼
Acta Crystallogr Sect E Struct Rep Online. 2012 Feb 1;68(Pt 2):o398-9. doi: 10.1107/S1600536812000815. Epub 2012 Jan 14.
8
4-{[5-(4-Chloro-phen-yl)-1-(4-fluoro-phen-yl)-1H-pyrazol-3-yl]carbon-yl}-N-ethyl-piperazine-1-carboxamide.4-{[5-(4-氯苯基)-1-(4-氟苯基)-1H-吡唑-3-基]羰基}-N-乙基哌嗪-1-甲酰胺
Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 1;67(Pt 7):o1747-8. doi: 10.1107/S1600536811023178. Epub 2011 Jun 18.
9
N-(6-Bromo-meth-yl-2-pyrid-yl)acetamide.N-（6-溴甲基-2-吡啶基）乙酰胺
Acta Crystallogr Sect E Struct Rep Online. 2010 Sep 4;66(Pt 10):o2500. doi: 10.1107/S1600536810035026.
10
6-(4-Bromo-phen-yl)-2-eth-oxy-4-(2,4,6-trimethoxy-phen-yl)nicotinonitrile.6-（4-溴苯基）-2-乙氧基-4-（2,4,6-三甲氧基苯基）烟腈
Acta Crystallogr Sect E Struct Rep Online. 2009 Oct 31;65(Pt 11):o2914-5. doi: 10.1107/S1600536809043943.

引用本文的文献

1
3-(4-Chloro-phen-oxy)-1-(4-meth-oxy-phen-yl)-4-(4-nitro-phen-yl)azetidin-2-one.3-（4-氯苯氧基）-1-（4-甲氧基苯基）-4-（4-硝基苯基）氮杂环丁烷-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2011 May 1;67(Pt 5):o1101-2. doi: 10.1107/S1600536811013018. Epub 2011 Apr 13.
2
7-Benzenesulfonamido-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-carboxylic acid monohydrate.7-苯磺酰胺基-3-甲基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸一水合物
Acta Crystallogr Sect E Struct Rep Online. 2009 Dec 9;66(Pt 1):o73-4. doi: 10.1107/S1600536809051769.
3
Synthesis of some new mono- and bis-polycyclic aromatic spiro and bis-nonspiro-beta-lactams.

本文引用的文献

1
4-(9-Anthr-yl)-1-(2-methoxy-phen-yl)spiro-[azetidin-3,9'-xanthen]-2-one.4-（9-蒽基）-1-（2-甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2009 Feb 28;65(Pt 3):o626-7. doi: 10.1107/S1600536809005200.
2
4-(9-Anthr-yl)-1-(1-naphth-yl)spiro-[azetidine-3,9'-xanthen]-2-one n-hexane hemisolvate.4-（9-蒽基）-1-（1-萘基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮正己烷半溶剂化物
Acta Crystallogr Sect E Struct Rep Online. 2008 Nov 29;64(Pt 12):o2466-7. doi: 10.1107/S1600536808039305.
3
4-(9-Anthr-yl)-1-(4-methoxy-phen-yl)spiro-[azetidin-3,9'-xanthen]-2-one.
一些新的单环和双环芳族螺和双非螺β-内酰胺的合成。
Molecules. 2010 Jan 22;15(1):515-31. doi: 10.3390/molecules15010515.
4-（9-蒽基）-1-（4-甲氧基苯基）螺[氮杂环丁烷-3,9'-呫吨]-2-酮
Acta Crystallogr Sect E Struct Rep Online. 2008 Apr 26;64(Pt 5):o902-3. doi: 10.1107/S1600536808010908.
4
A short history of SHELX.SHELX简史。
Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22. doi: 10.1107/S0108767307043930. Epub 2007 Dec 21.
5
Synthesis of anticancer beta-lactams: mechanism of action.抗癌β-内酰胺类药物的合成：作用机制
Bioorg Med Chem. 2004 May 15;12(10):2523-8. doi: 10.1016/j.bmc.2004.03.033.
6
Stereoselective synthesis of beta-lactams with polyaromatic imines: entry to new and novel anticancer agents.含多芳族亚胺的β-内酰胺的立体选择性合成：通向新型抗癌剂之路。
J Med Chem. 2003 Jan 2;46(1):12-5. doi: 10.1021/jm0255825.
7
Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of some chrysene derivatives.多环芳香化合物作为抗癌剂：一些屈衍生物的合成与生物学评价
Bioorg Med Chem Lett. 1998 Oct 20;8(20):2877-80. doi: 10.1016/s0960-894x(98)00520-4.